Company Announcements

• WELLSTAR continues to demonstrate strong growth and business momentum through its sustained organic growth and strong acquisition pipeline. The business is ahead of its internal expectations and has updated its guidance to $74 million⁽¹⁾ in total revenue and $22 million⁽¹⁾ in Adjusted EBITDA⁽²⁾ for fiscal 2025, ending the year with total ARR of $62 million and an exit ARR⁽³⁾ of approximately $80 million.
• WELLSTAR has executed three LOIs for acquisitions that will drive approximately $15 million in ARR, $16 million in revenues and over $5 million in Adjusted EBITDA on an annualized basis.
• WELLSTAR’s recently launched Nexus AI™ solution has generated significant early momentum. As a pre-qualified vendor for Canada Health Infoway’s AI Scribe Program, eligible primary care clinicians can now receive a fully-funded Nexus AI license for 12 months.

VANCOUVER, British Columbia & TORONTO--(BUSINESS WIRE)--Jul. 15, 2025-- WELL Health Technologies Corp. (TSX: WELL) (“WELL” or the “Company”), a company focused on positively impacting health outcomes by leveraging technology to empower healthcare providers and their patients, is pleased to provide a corporate update highlighting continued momentum across its majority-owned subsidiary, WELLSTAR Technologies Corp. (“WELLSTAR”). WELLSTAR is tracking ahead of internal expectations, supported by robust organic growth, a strong acquisition pipeline, and accelerating adoption of its Nexus AI solution.

WELLSTAR continues to demonstrate strong growth and execution, fueled by accelerating demand for its digital health solutions and steady progress across its platform. The business is tracking ahead of internal expectations and has updated its guidance for fiscal 2025 to over $74 million ⁽¹⁾ in revenue and $22 million⁽¹⁾ in Adjusted EBITDA⁽²⁾. WELLSTAR is also expected to end the year with total annual recurring revenue (ARR) of approximately $62 million and an exit ARR⁽³⁾ of approximately $80 million, supported by robust organic expansion, continued adoption of its AI-powered tools, and inclusive of completing three acquisitions that are currently in signed LOI stage.

Amir Javidan, CEO of WELLSTAR commented, “We’ve had an excellent first half to 2025 as both our organic and inorganic growth engines are levelling up and are poised to deliver an outstanding, breakout performance for WELLSTAR in 2025. At the beginning of the year, we set an ambitious goal of reaching $100M in revenues on a run-rate basis in the next couple of years and based on the latest forecasts, we believe we may be approaching that goal a few quarters earlier than previously anticipated. Our current goal for year-end exit ARR for fiscal 2025 is $80 million which would represent a 50% increase over last year’s exit ARR figure.

Darren Hoegler, CFO of WELLSTAR commented, “This upward revision reflects stronger-than-expected traction across WELLSTAR’s core product suite as well as strong execution in the company’s capital allocation program. We currently have three signed LOIs with targets that all deliver high-margin SaaS solutions and would be highly accretive to our business. I’m also pleased to report that the two acquisitions that were completed in Q4 2024 are both operating well and tracking in alignment with or ahead of our plan. Our objective is to ensure disciplined execution and that the company continues to be positioned as a category leader in Canadian digital health, delivering durable, capital-efficient growth with significant operating leverage over time.”

Three LOIs Executed as WELLSTAR Executes on Deep Acquisition Pipeline

WELLSTAR has executed three letters of intent (LOIs) for acquisitions that are expected to contribute approximately $15 million in ARR, $16 million in revenue, and over $5 million in Adjusted EBITDA on an annualized run-rate basis. These prospective additions reflect WELLSTAR’s continued focus on disciplined, accretive growth through the acquisition of complementary digital health assets that strengthen its core platform and expand its national footprint.

The acquisitions are aligned with WELLSTAR’s long-term strategy to build a technology-enabled healthcare infrastructure that is efficient, scalable, and outcomes-driven. Each target adds strategic value by extending WELLSTAR’s clinician enablement capabilities. The integrated nature of WELLSTAR’s platform enables smooth onboarding and operational alignment, allowing new assets to benefit from shared infrastructure and drive incremental impact across the broader business.

WELLSTAR continues to advance a deep and well-qualified acquisition pipeline, with additional opportunities under review.

Strong Early Traction for Nexus AI with Clinicians Nationwide

Since its launch on May 7, 2025, Nexus AI has seen strong adoption, with over 2,400 providers signed up across primary care clinics, hospitals, and regional health authorities. Nexus AI’s first feature, an ambient medical scribe for real-time clinical documentation, is already demonstrating meaningful value for providers by reducing administrative burden and cognitive load. AI medical scribe technology has been shown to save providers up to two hours per day in charting and documentation⁽⁴⁾.

Nexus AI serves as the central platform for WELLSTAR’s expanding suite of AI-powered capabilities, including disease detection, medical coding and billing automation, and clinical decision support. Its compatibility with Canada’s leading EMRs positions it as a scalable infrastructure layer for modern, intelligent healthcare delivery.

Clinician engagement with Nexus AI is expected to contribute to WELLSTAR’s recurring SaaS revenue and margin profile as deployments scale. Just as importantly, the platform’s ability to orchestrate complex clinical workflows in an intuitive and context-aware way supports broader system-level efficiency and provider satisfaction.

As a pre-qualified vendor of the Canada Health Infoway AI Scribe Program, eligible primary care clinicians across Canada will receive a fully-funded license for 12 months of Nexus AI. WELLSTAR recognizes this as a transformative opportunity to advance Canada’s vision of connected care, where AI-enabled technologies reduce physician burnout, improve patient experience, and allow providers to focus more on engagement and less on documentation. By delivering accurate, secure documentation at the point of care, Nexus AI empowers providers to reclaim meaningful patient connections and supports a broader effort to integrate AI technologies that promote more connected, patient-centred care.

Footnotes:

1. WELLSTAR’s guidance of $74 million in revenue and $22 million in Adjusted EBITDA in fiscal 2025 includes the impact from the three LOIs noted herein which will contribute approximately $4 million in revenue and $1 million in Adjusted EBITDA for inclusion in fiscal 2025. Note that this figure does not include certain shared services that are provided by WELL Health to WELLSTAR.
2. Adjusted EBITDA is a non-GAAP financial measure. Please refer to WELL’s most recent Management’s Discussion and Analysis (MD&A), available under the Company’s profile on SEDAR+ at www.sedarplus.ca, for further details including definitions and reconciliations to the nearest IFRS measure.
3. Exit ARR or Annual Recurring Revenue is based on the Company’s revenue run-rate or ARR as annualized based on the last quarter of the year. The projected Exit ARR of approximately $80 million includes contribution from the three LOIs noted herein.
4. Source: OntarioMD, AI scribes show promising results in helping family doctors and nurse practitioners spend more time with patients and less time on paperwork, September 11, 2024. https://www.ontariomd.ca/pages/ai-scribes-promising-results.aspx

WELL HEALTH TECHNOLOGIES CORP.

Per: “Hamed Shahbazi”

Hamed Shahbazi

Chief Executive Officer, Chairman and Director

WELL Health Technologies Inc.

About WELL Health Technologies Corp.

WELL’s mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL’s comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL’s solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL’s solutions are focused on specialized markets such as the gastrointestinal market, women’s health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol “WELL” and on the OTC Exchange under the symbol “WHTCF”. To learn more about the Company, please visit: www.well.company.

Forward-Looking Statements

Certain statements in this press release, constitute “forward-looking information” and “forward looking statements” (collectively, “forward looking statements”) within the meaning of applicable Canadian securities laws, including the guidance related to revenue and adjusted EBITDA, and the expected pipeline of future acquisition targets (and the associated run-rate revenue). Forward-looking statements are necessarily based upon management’s expectations, while considered reasonable by WELL as of the date of such statements, are outside of WELL’s control and are inherently subject to business, economic and other uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to the ability to continue to offer its products and services, complete the acquisitions, and the acquisition companies having the expected revenue and Adjusted EBITDA profiles based on WELL’s diligence.

Known and unknown risk factors, many of which are beyond the control of WELL could cause the actual plans to differ materially from the results implied by such forward-looking statements. Such risk factors include losing customers to competitors, cybersecurity threats which prevent WELLSTAR from being able to continually offer its products, not completing the three acquisitions discussed above, and the other risks discussed under the section entitled “Risk Factors” in WELL’s most recent annual information form, which is available under the Company’s respective SEDAR+ profile at www.sedarplus.ca which could affect WELL’s and WELLSTAR’s business. The risk factors are not intended to represent a complete list of the factors that could affect WELL or WELLSTAR and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. WELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250715085231/en/

For more information:
Tyler Baba
Investor Relations, Manager
investor@well.company
604-628-7266

Source: WELL Health Technologies Corp.